Cargando…

Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma

We aimed to study mechanisms controlling metastatic outgrowth of melanoma into clinically relevant lesions, a critical process responsible for the majority of melanoma deaths. To this end, we developed novel in vivo models and identified molecular events that can be ascribed to their distinct phenot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oria, Victor O., Zhang, Hongyi, Zito, Christopher R., Rane, Chetan K., Ma, Xian-Yong, Provance, Olivia K., Tran, Thuy T., Adeniran, Adebowale, Kluger, Yuval, Sznol, Mario, Bosenberg, Marcus W., Kluger, Harriet M., Jilaveanu, Lucia B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226089/ https://www.ncbi.nlm.nih.gov/pubmed/35737114 http://dx.doi.org/10.1007/s00018-022-04364-5

Ejemplares similares

19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA
por: Oria, Victor, et al.
Publicado: (2020)

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors
por: Shuch, Brian, et al.
Publicado: (2015)

Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells
por: Tran, Thuy T., et al.
Publicado: (2021)

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
por: Aziz, Saadia A, et al.
Publicado: (2013)

Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases
por: Weiss, Sarah A., et al.
Publicado: (2020)

Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens
por: Baine, Marina K., et al.
Publicado: (2015)

Vascularity of primary and metastatic renal cell carcinoma specimens
por: Aziz, Saadia A, et al.
Publicado: (2013)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
por: Aziz, Saadia A, et al.
Publicado: (2014)

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
por: Damsky, William, et al.
Publicado: (2019)

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
por: Schoenfeld, David A., et al.
Publicado: (2022)

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
por: Tran, Thuy T., et al.
Publicado: (2023)

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
por: Caulfield, Jasmine I, et al.
Publicado: (2023)

Characterizing disease states from topological properties of transcriptional regulatory networks
por: Tuck, David P, et al.
Publicado: (2006)

SIMVI reveals intrinsic and spatial-induced states in spatial omics data
por: Dong, Mingze, et al.
Publicado: (2023)

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
por: Djureinovic, Dijana, et al.
Publicado: (2023)

Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure
por: Qu, Rihao, et al.
Publicado: (2022)

Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma
por: Su, David, et al.
Publicado: (2023)

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
por: Jilaveanu, L.B., et al.
Publicado: (2014)

Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy
por: Tran, Thuy T., et al.
Publicado: (2019)

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
por: Schoenfeld, David A, et al.
Publicado: (2023)

Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases
por: Lu, Benjamin Y, et al.
Publicado: (2021)

[(11)C]Methionine and [(11)C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis
por: Tran, Thuy T., et al.
Publicado: (2020)

Monoclonal and Polyclonal Antibodies Specific to Human Fibromodulin
por: Farahi, Lia, et al.
Publicado: (2019)

Fibromodulin – A New Target of Osteoarthritis Management?
por: Li, Chenshuang, et al.
Publicado: (2019)

Fibromodulin Ablation Exacerbates the Severity of Acute Colitis
por: Halasi, Marianna, et al.
Publicado: (2022)

A modified IL-18 drug in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma
por: Schoenfeld, David, et al.
Publicado: (2023)

Impact of healthcare worker shift scheduling on workforce preservation during the COVID-19 pandemic
por: Kluger, Dan M., et al.
Publicado: (2020)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

Fibromodulin Enhances Angiogenesis during Cutaneous Wound Healing
por: Zheng, Zhong, et al.
Publicado: (2015)

The role of fibromodulin in cancer pathogenesis: implications for diagnosis and therapy
por: Pourhanifeh, Mohammad Hossein, et al.
Publicado: (2019)

The role of fibromodulin in inflammatory responses and diseases associated with inflammation
por: Zhao, Feng, et al.
Publicado: (2023)

Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells
por: Zito, Christopher R., et al.
Publicado: (2012)

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer
por: Dhodapkar, Kavita, et al.
Publicado: (2014)

Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer
por: Nadler, Yasmine, et al.
Publicado: (2008)

Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models
por: Parisi, Fabio, et al.
Publicado: (2010)

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
por: Rubinstein, Jill C, et al.
Publicado: (2010)

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells
por: Halaban, Ruth, et al.
Publicado: (2010)

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
por: Kluger, Harriet M, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_4jvhp6mnrpuo82ml4j433n8240